There is no cure that eliminates the herpes simplex virus from your body, but you can stop outbreaks from happening, shorten them when they do, and dramatically reduce the chance of passing the virus to someone else. Daily antiviral therapy cuts recurrent outbreaks by 70% to 80%, and combining it with condoms can make transmission to a partner unlikely. The virus hides in nerve cells in a dormant state that current medications can’t reach, but the tools available right now give most people near-complete control over symptoms and shedding.
Why Herpes Can’t Be Fully Eliminated Yet
After the initial infection, the herpes simplex virus travels along nerve fibers and settles into clusters of nerve cells near the spine (for genital herpes) or near the base of the skull (for oral herpes). Inside those neurons, the viral DNA forms small circular loops that sit quietly in the cell nucleus, producing almost no viral proteins. Your immune system can’t detect something that isn’t actively making viral material, so these dormant copies survive indefinitely.
Periodically, poorly understood triggers cause the virus to “wake up.” It begins producing proteins in a burst that doesn’t follow its normal replication sequence, essentially testing whether conditions are right to make new virus. If enough of those early proteins accumulate, full replication kicks in, new virus particles travel back down the nerve fiber to the skin, and you get either a visible outbreak or invisible viral shedding. Antiviral medications work by blocking that replication step, but they can’t touch the dormant DNA sitting silently in your nerve cells.
Antiviral Medications: The Most Effective Option
Prescription antivirals are the backbone of herpes management. Three drugs are available: acyclovir, valacyclovir, and famciclovir. All work by the same basic mechanism, interfering with the virus’s ability to copy its DNA. Valacyclovir is the most commonly prescribed because it’s absorbed more efficiently, meaning fewer pills per day.
You can use antivirals in two ways. Episodic therapy means taking them at the first sign of an outbreak (tingling, itching, redness) for a few days to shorten and lessen the episode. Suppressive therapy means taking a low dose every day whether or not you have symptoms. For people with frequent outbreaks, suppressive therapy reduces recurrences by 70% to 80%. Many people on daily suppressive therapy go a year or more without a single outbreak.
Suppressive therapy also has a major benefit for partners. Daily valacyclovir at 500 mg significantly decreases the rate of HSV-2 transmission to an uninfected partner. This matters because herpes can spread even when no sores are visible.
Asymptomatic Shedding: The Hidden Risk
One of the trickiest aspects of herpes is that the virus can reach the skin surface and be contagious without causing any noticeable symptoms. During the first six months after infection, this invisible shedding can happen on 20% to 40% of days. Over time it decreases, but even with long-term infection, shedding still occurs on roughly 5% to 20% of days. People who have never had a recognized outbreak shed about 50% less than those who have had visible symptoms, but they still shed.
This is why relying solely on avoiding sex during outbreaks isn’t enough to prevent transmission. Suppressive antiviral therapy and barrier methods are the most reliable ways to reduce that risk during the periods when you feel completely fine.
How Condoms Reduce Transmission
Condoms are highly effective at blocking herpes transmission, though the degree of protection depends on the direction of transmission. A large study of over 900 couples where one partner had HSV-2 found that condoms reduced per-act transmission from men to women by 96%. Protection from women to men was lower, around 65%, likely because more skin-to-skin contact occurs in areas the condom doesn’t cover. Combined with daily suppressive antivirals, the overall risk of passing herpes to a partner drops to very low levels.
Managing Outbreak Triggers
While antivirals do the heavy lifting, avoiding known triggers can reduce how often the virus reactivates. The most consistently documented triggers include:
- Stress and fatigue. Physical or emotional exhaustion weakens the local immune responses that keep the virus dormant in nerve cells. Sleep deprivation is a common culprit.
- Sun and wind exposure. UV radiation is a well-established trigger for oral herpes outbreaks. Using lip balm with SPF and avoiding prolonged unprotected sun exposure on the face helps.
- Illness or immune suppression. A bad cold, the flu, or anything that taxes your immune system can open a window for reactivation.
- Poor diet. Nutritional deficits, particularly when combined with stress, are associated with more frequent outbreaks.
None of these triggers guarantee an outbreak, and avoiding them won’t replace antiviral therapy. But people who track their outbreaks often notice patterns that help them anticipate and prepare.
L-Lysine and Other Supplements
L-lysine is the most studied supplement for herpes prevention. In a six-month trial, participants taking lysine averaged 2.4 times fewer outbreaks than those on placebo, with shorter healing times and milder symptoms. However, the dose matters considerably. Supplementation below 1 gram per day appears ineffective for both prevention and treatment. Doses above 3 grams per day showed the most benefit in terms of patients’ subjective experience of the disease.
Lysine is an amino acid that competes with arginine, another amino acid the herpes virus needs for replication. Some people adjust their diet to favor lysine-rich foods (dairy, fish, chicken) and limit arginine-heavy foods (nuts, chocolate, seeds), though this dietary approach hasn’t been rigorously tested in clinical trials. Lysine is generally safe at supplemental doses, but it works best as an add-on to antiviral therapy rather than a replacement.
Over-the-Counter Topical Treatments
For cold sores (oral herpes), docosanol cream is the main FDA-approved over-the-counter option. It works by blocking the virus from entering healthy skin cells, which can modestly shorten an outbreak if applied at the very first sign of tingling. It typically reduces healing time by about a day compared to doing nothing. Topical treatments for genital herpes are far less effective than oral antivirals, and the CDC’s treatment guidelines focus on oral medications rather than creams for genital outbreaks.
Pain relief during an outbreak is straightforward. Cool compresses, loose clothing, and over-the-counter pain relievers can ease discomfort. Keeping sores clean and dry helps them heal faster.
Reducing Transmission to a Partner
If you have herpes and your partner doesn’t, the combination of three strategies provides the strongest protection: daily suppressive antiviral therapy, consistent condom use, and avoiding sexual contact during active outbreaks or when you feel prodromal symptoms like tingling or itching. No single method is perfect on its own, but layered together they make transmission uncommon.
Having an honest conversation with your partner matters too. Knowing the status of both partners allows for informed decisions. IgG blood tests can detect herpes antibodies, but timing and accuracy are important considerations. Testing too soon after a possible exposure can produce a false negative, and low-positive results near the test’s cutoff value have a higher chance of being false positives. If results are ambiguous, a follow-up test or a different testing method may be needed.
What a Typical Long-Term Experience Looks Like
For most people, herpes becomes less of a problem over time even without medication. Outbreaks tend to be most frequent and severe in the first year after infection, then gradually decrease in both frequency and intensity. Many people with HSV-2 eventually go years between outbreaks. HSV-1 genital infections tend to recur even less often than HSV-2.
With daily suppressive therapy, the majority of people experience few or no outbreaks at all. Some people take antivirals for a year or two during the most active period and then stop to see whether outbreaks have naturally decreased. Others stay on suppressive therapy long-term, particularly if they have an uninfected partner. The medications have been used safely for decades with minimal side effects.
Moderna currently has a therapeutic vaccine candidate (mRNA-1608) in Phase 1/2 clinical trials for people who already have genital HSV-2. It aims to reduce outbreaks and shedding in people who are already infected. Results are still pending, but the use of mRNA technology, proven successful with COVID-19 vaccines, has generated significant interest in the herpes research community.